GSK plc — Form 6-K summary
Reporting context: Filed for October 2026 and signed October 12, 2026. The filing reports transactions in GSK securities by persons discharging managerial responsibilities (PDMRs) and their closely associated persons; it is not an earnings or financial-results update.
Reported transactions
- Multiple executives and associated persons acquired GSK ordinary shares through the Share Reward Plan, including dividend reinvestments relating to the dividend paid October 8 and plan purchases on October 9. Disclosed prices ranged from £17.5852 to £17.6650 per share.
- Reported ordinary-share amounts include 3 shares for CEO Luke Miels, 14 for CFO Julie Brown, and 14 for several other executives under the plan. Additional dividend-reinvestment and ISA transactions were reported for executives and associated persons, including 1,182 shares for Iain Whyte at £17.5904.
- President, US Maya Martinez-Davis acquired 10.155 notional GSK ADSs in her executive supplemental savings plan account at $47.0200 on October 7.
Financial performance and outlook
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or operating outlook figures. It includes no management commentary on business performance, material contingencies, or unusual items beyond the securities transactions described.
Investor verification points
- Check the original transaction notices for each PDMR/PCA, security, transaction date, price, volume, and transaction type; the filing contains numerous separate entries.
- Confirm the distinction between ordinary shares, ADSs, dividend reinvestments, Share Reward Plan purchases, and transactions within savings or ISA accounts.
- Do not treat these routine plan-related acquisitions as evidence of a change in GSK’s financial outlook; this filing reports no operating results.